NELSON, M. Bud,SAVITHRI, Dhanalekshmi,BALASUBRAMANIAN, Thiagarajan
申请号：
USUS2014/046937
公开号：
WO2015/009882A3
申请日:
2014.07.17
申请国别(地区):
WO
年份:
2015
代理人:
摘要：
Compounds inhibit Nrf2 activity for treatment of mycobacterial infection, granulomatous inflammation, tuberculosis, viral infection, or cancer include 5-((2-(2-cyano-3-methylguanidino)ethylthio)methyl)-1 H-imidazole-4carboxamide 2-cyano-1-(2-( ( 4-hydrazinecarbonyl)-1 H-im idazol-5-yl)methylthio )ethyl-3-methylguanidine 5-((2-(2-cyano-3-methylguanidino)ethylthio)methyl)-1 H-imidazole-2-carboxamide 2-cyano-1-(2-((2-hydrazinecarbonyl)-1 H-imidazol-5-yl)methylthio)ethyl-3-methylguanidine 2-cyano-1-methyl-3-(2-((4- methyl-1 H-imidazol-5-yl)methylamino)ethylguanidine 3-( ( 2-(2-cyano-3-m ethylg uan idino) ethylth io) m ethyl)pyrazine-2-carboxamide 6-( ( 2-(2-cyano-3-m ethylg uan idino) ethylth io) m ethyl)pyrazine-2-carboxamide 2-cyano-1-(2-( ( 4-hydrazinecarbonyl)pyridine-2-yl) methylthio )ethyl-3-methylguanidine and 2-cyano-1-(2-( ( 4-hydrazinecarbonyl)pyridine-3-yl) methylthio)ethyl-3-methylguanidine or a pharmaceutically acceptable salt thereof.Linvention concerne un composé de formule (I), des sels pharmaceutiquement acceptables de celui-ci, et des compositions contenant ledit composé.
